Liquidia (NASDAQ:LQDA) Sees Large Volume Increase Following Analyst Upgrade

Liquidia Corporation (NASDAQ:LQDA) shares saw unusually-high trading volume on Wednesday after BTIG Research upgraded the stock from a neutral rating to a buy rating. BTIG Research now has a $70.00 price target on the stock. 7,091,868 shares changed hands during mid-day trading, an increase of 235% from the previous session’s volume of 2,115,398 shares. The stock last traded at $34.1210 and had previously closed at $26.81.

A number of other analysts have also recently weighed in on LQDA. Stephens set a $130.00 price objective on shares of Liquidia in a report on Friday, July 24th. HC Wainwright lowered their target price on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating for the company in a report on Friday, October 2nd. Citigroup reaffirmed a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $30.00 target price (down from $108.00) on shares of Liquidia in a research report on Friday, October 2nd. Finally, Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $79.69.

Insider Activity

In other Liquidia news, CEO Roger Jeffs sold 32,744 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $932,549.12. Following the completion of the sale, the chief executive officer owned 1,125,848 shares in the company, valued at approximately $32,064,151.04. The trade was a 2.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Rajeev Saggar sold 50,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total value of $3,703,000.00. Following the completion of the sale, the insider directly owned 142,265 shares of the company’s stock, valued at $10,536,145.90. The trade was a 26.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 745,194 shares of company stock worth $41,081,702 over the last ninety days. 25.60% of the stock is owned by corporate insiders.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six pending patent, antitrust, trade-secret and contract disputes with United Therapeutics. The agreement allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH), reducing the risk of a market disruption or prolonged litigation. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA net sales reached $222.7 million, and Liquidia had $396.1 million in cash and cash equivalents at September 30. Management said it expects to fund settlement payments and clinical development from cash and operating sales without issuing new financing. Liquidia United Therapeutics litigation settlement
• Positive Sentiment: BTIG upgraded Liquidia from “neutral” to “buy” with a $70 price target, while Needham maintained a “buy” rating and lowered its target to $58. Both targets imply substantial upside based on the company’s recent trading level.
• Neutral Sentiment: Liquidia plans to continue developing YUTREPIA and its investigational L606 formulation, potentially supporting longer-term growth beyond the current PAH business.
• Negative Sentiment: The settlement requires Liquidia to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust claims. The payments will substantially reduce the company’s cash balance and could limit investment flexibility.
• Negative Sentiment: Liquidia agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing some commercial opportunities.
• Neutral Sentiment: The CEO, CFO and other insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax obligations from vested equity awards. Because the sales were not discretionary open-market transactions, they are a limited standalone signal, although recent insider activity remains heavily weighted toward selling.

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new stake in Liquidia in the 2nd quarter valued at approximately $29,694,000. Bank of America Corp DE raised its stake in shares of Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new position in shares of Liquidia during the 1st quarter worth approximately $9,337,000. Eversept Partners LP raised its stake in shares of Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after buying an additional 167,949 shares in the last quarter. Finally, Seven Fleet Capital Management LP lifted its holdings in shares of Liquidia by 124.5% in the 1st quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after buying an additional 113,609 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Stock Up 29.8%

The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The firm has a fifty day moving average price of $63.40 and a 200 day moving average price of $61.76. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of 25.41 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter last year, the firm earned ($0.49) earnings per share. The firm’s quarterly revenue was up 1842.1% compared to the same quarter last year. As a group, sell-side analysts expect that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).